Skip to main content

Table 1 Baseline characteristics

From: Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

Patient characteristics

N = 83

Age, median (range), years

57.0 (30–78)

  ≥ 65 years, %

19

Male, %

70

KPS, %

 

 90–100

70

 70–80

30

Current site(s) of metastasis, %

 

 Hepatic/liver

83

 Abdomen/peritoneal

53

 Lung/thoracic

18

No. of metastatic sites, %

 

 1

35

 2

43

 3

19

 4

2

CA 19–9, median (range), U/mLa

602.8 (0.93–1000)

Biliary stent, %

1

  1. a CA 19–9 value above laboratory-defined upper limit of quantitation (1000 U/mL) is listed as 1000 U/mL
  2. CA 19–9 carbohydrate antigen 19–9, KPS Karnofsky performance status